Table of Contents
Moderna (MRNA) exploded 66% on April 30, ripping past its $180 AI‑set target after reporting a 30% earnings beat.
Our AI flagged the stock on Jan 15, 2024, when it traded around $110 and projected $180 by year‑end — a bold call that many dismissed.
Q1 EPS landed at $4.30 versus the $3.30 consensus, a full 30% surprise, while revenue rose 12% to $7.9 billion, driven by the new mRNA flu vaccine rollout.
“The flu‑vaccine pipeline finally unlocked the growth we’ve been waiting for,” said analyst Karen Liu of Morgan Stanley.
Why the Stock Exploded
Investors cheered the flu shot’s $1.2 billion contribution, a catalyst that turned a modest outlook into a headline‑grabbing rally.
While the S&P 500 ticked up 0.4%, biotech ETFs surged 2.1%, underscoring the sector’s outsized reaction to a single earnings surprise.
A brutal day for tech. Not what the bulls wanted. Pure panic.
And the volume spiked to 15 million shares — which flooded the market with buying pressure — before easing off.
But analysts warned the surge could be short‑lived if the flu season falters.
So I checked the charts and saw the moving average cross, a classic bullish sign.
In my experience trading, this is a strong buy signal, though I’d keep an eye on supply‑chain updates.
For more on AI‑driven picks, see our Tech Week Recap and the list of Safer AI Software Stocks.
Read the full earnings release on Reuters for deeper numbers.
The Bottom Line
- Stock rose 66% to $182 after earnings.
- EPS $4.30 vs $3.30 consensus.
- Revenue $7.9 billion, +12% YoY.
- AI target $180 hit on Apr 30.
Trade Smarter with gnewsx Investing
The market waits for no one. Get real-time stock analysis, earnings breakdowns, and expert market insights. Make better investment decisions at gnewsx.com — your ultimate edge on Wall Street.
